Evidence map›Paper›PMID 40293594›Full record

ArticleBulletin of experimental biology and medicine2025

Clinical Significance of Epigenetic Factors in the Development of Tumor Cell Resistance to the Cytotoxic Activity of Macrophages.

O V Kovaleva, P A Podlesnaya, E S Kudinova, V V Sinyov, V V Mochalnikova, N E Kushlinskii, A N Gratchev

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

O V KovalevaN. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, Moscow, Russia. ovkovaleva@gmail.com.
P A PodlesnayaN. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, Moscow, Russia.
E S KudinovaN. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, Moscow, Russia.
V V SinyovN. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, Moscow, Russia.
V V MochalnikovaN. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, Moscow, Russia.
N E KushlinskiiN. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, Moscow, Russia.
A N GratchevN. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The expression of long non-coding RNAs (lncRNAs) PSMB8-AS1 and IGFL2-AS1, as well as associated microRNAs miR-802 and miR-382-3p, was analyzed in 42 paired samples of non-small cell lung cancer (NSCLC) with subsequent evaluation of their diagnostic and prognostic significance. The expression of PSMB8-AS1 was reduced in tumor tissue compared to normal lung tissue, while the expression levels of IGFL2-AS1, miR-802, and miR-382-3p were increased. The analysis of the clinical significance of the studied molecules showed that the expression of PSMB8-AS1 correlated with the histological type and localization of the tumor (r = -0.532, p = 0.0003, and r = -0.475, p = 0.003, respectively). ROC analysis for PSMB8-AS1 in the group of patients with squamous cell carcinoma showed that the area under the ROC curve was 0.904 (p < 0.0001), indicating good quality of the diagnostic model and allows us to use the data obtained to further verify it. The analysis of the prognostic significance has shown that the studied non-coding RNAs in general are not prognostic factors for NSCLC. Additional subgroup analysis showed that PSMB8-AS1 is an unfavorable prognostic factor for squamous cell lung cancer (hazard ratio (HR)= 4.482, p = 0.027). Further investigation of non-coding RNAs in NSCLC is promising for identifying new markers for the diagnosis and prognosis of this disease.

Indexed as

Carcinoma, Non-Small-Cell LungCarcinoma, Squamous CellEpigenesis, GeneticLung NeoplasmsMacrophagesRNA, Long NoncodingAgedBiomarkers, TumorClinical RelevanceFemaleGene Expression Regulation, NeoplasticHumansMaleMicroRNAsMiddle AgedPrognosisBiomarkers, TumorMicroRNAsRNA, Long NoncodingdiagnosislncRNAmicroRNAnon-small cell lung cancerprognosis

Identifiers

PMID40293594

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.